[go: up one dir, main page]

DK1063995T3 - Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator - Google Patents

Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator

Info

Publication number
DK1063995T3
DK1063995T3 DK99916907T DK99916907T DK1063995T3 DK 1063995 T3 DK1063995 T3 DK 1063995T3 DK 99916907 T DK99916907 T DK 99916907T DK 99916907 T DK99916907 T DK 99916907T DK 1063995 T3 DK1063995 T3 DK 1063995T3
Authority
DK
Denmark
Prior art keywords
nmda receptor
receptor complex
opioid antagonist
combination
complex modulator
Prior art date
Application number
DK99916907T
Other languages
Danish (da)
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Philippe Durbin
Original Assignee
Merck Sante Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante Sas filed Critical Merck Sante Sas
Application granted granted Critical
Publication of DK1063995T3 publication Critical patent/DK1063995T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99916907T 1998-03-26 1999-03-26 Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator DK1063995T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (fr) 1998-03-26 1998-03-26 Combinaison pharmaceutique d'un antagoniste opioide et d'un modulateur du complexe récepteur de NMDA, utilisée dans le traitement de la dépendance à l'alcool ou de la toxicomanie
PCT/EP1999/002337 WO1999048500A1 (fr) 1998-03-26 1999-03-26 Combinaison destinee au traitement de la dependance a l'alcool et aux drogues contenant un antagoniste d'opioides et un modulateur du complexe du recepteur nmda

Publications (1)

Publication Number Publication Date
DK1063995T3 true DK1063995T3 (da) 2003-03-10

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99916907T DK1063995T3 (da) 1998-03-26 1999-03-26 Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator

Country Status (17)

Country Link
US (1) US6512009B1 (fr)
EP (2) EP0945133A1 (fr)
KR (1) KR20010034678A (fr)
AT (1) ATE230993T1 (fr)
AU (1) AU758569B2 (fr)
BR (1) BR9909138A (fr)
CA (1) CA2325739C (fr)
CZ (1) CZ296367B6 (fr)
DE (1) DE69904922T2 (fr)
DK (1) DK1063995T3 (fr)
ES (1) ES2190205T3 (fr)
HU (1) HU226555B1 (fr)
NO (1) NO319313B1 (fr)
PL (1) PL193241B1 (fr)
RU (1) RU2226107C2 (fr)
SK (1) SK284623B6 (fr)
WO (1) WO1999048500A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (fr) * 2000-01-22 2001-07-26 Albert Shulman Methodes de traitement d'abus de substances
EP1262196A3 (fr) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combinaison d'un inhibiteur de la recapture de monoamines et d'un antagoniste opioique pour l'utilisation dans l'alcoolisme et la dépendance alcoolique
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
SI2561860T1 (en) 2002-05-31 2018-05-31 Titan Pharmaceuticals, Inc. An implantable polymeric device for prolonged release of buprenorphine
CA2507522C (fr) 2002-12-13 2015-02-24 Durect Corporation Systeme d'administration de medicaments par voie orale
EP1572164A2 (fr) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Formes posologiques orales comprenant des agents actifs au plan therapeutique dans des noyaux a liberation lente et des revetements de capsule en gelatine a liberation immediate
CN1777426A (zh) * 2003-03-31 2006-05-24 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
ZA200509063B (en) * 2003-05-30 2007-03-28 Titan Pharmaceuticals Inc Impiantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20100041689A1 (en) * 2006-12-19 2010-02-18 University Of Virginia Patent Foundation Combined Effects of Topiramate and Ondansetron on Alcohol Consumption
CA2706931C (fr) 2007-12-06 2015-05-12 Durect Corporation Formes posologiques pharmaceutiques orales
BRPI0908425B8 (pt) 2008-02-28 2021-05-25 Univ Of Virgina Patent Foundation métodos para predizer uma predisposição para desenvolver alcoolismo, e para predizer uma resposta para o tratamento contra alcoolismo, e, uso de um antagonista do receptor de serotonina 5-ht3
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
DK2801625T3 (en) 2010-07-02 2018-02-05 Univ Virginia Patent Foundation Molecular genetic approach to the treatment and diagnosis of alcohol and drug dependence
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
HK1220579A1 (zh) 2013-03-15 2017-05-12 Durect Corporation 用於降低溶解可变性的具有流变改性剂的组合物
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
KR102413459B1 (ko) 2016-07-06 2022-06-24 듀렉트 코퍼레이션 약물 조성물, 장벽 층 및 약물 층을 갖는 경구 투여 형태
WO2023023038A1 (fr) * 2021-08-17 2023-02-23 Yale University Compositions et méthodes de traitement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
CA2220768A1 (fr) * 1996-03-13 1997-09-18 Yale University Traitements pour cesser de fumer impliquant l'utilisation de naltrexone et de composes associes

Also Published As

Publication number Publication date
EP1063995B1 (fr) 2003-01-15
HU226555B1 (en) 2009-03-30
KR20010034678A (ko) 2001-04-25
EP1063995A1 (fr) 2001-01-03
HUP0101546A3 (en) 2002-10-28
ES2190205T3 (es) 2003-07-16
NO20004788L (no) 2000-11-24
HUP0101546A2 (hu) 2001-09-28
US6512009B1 (en) 2003-01-28
NO20004788D0 (no) 2000-09-25
AU758569B2 (en) 2003-03-27
PL193241B1 (pl) 2007-01-31
ATE230993T1 (de) 2003-02-15
DE69904922D1 (de) 2003-02-20
CA2325739A1 (fr) 1999-09-30
DE69904922T2 (de) 2004-01-08
WO1999048500A1 (fr) 1999-09-30
HK1032542A1 (en) 2001-07-27
CZ20003525A3 (cs) 2001-04-11
CA2325739C (fr) 2007-05-15
SK14282000A3 (sk) 2001-05-10
PL343069A1 (en) 2001-07-30
CZ296367B6 (cs) 2006-02-15
BR9909138A (pt) 2000-12-05
EP0945133A1 (fr) 1999-09-29
NO319313B1 (no) 2005-07-11
AU3522699A (en) 1999-10-18
RU2226107C2 (ru) 2004-03-27
SK284623B6 (sk) 2005-08-04

Similar Documents

Publication Publication Date Title
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
DK0800519T3 (da) Steroidreceptormodulatorforbindelser og fremgangsmåder
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
NO20031266D0 (no) Kondenserte heterocykliske suksinimid-forbindelser og analoger derav, modulatorer for nukle¶r hormonreseptorfunksjon
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DK0812195T3 (da) Farmaceutisk sammensætning til piperidinoalkanolforbindelser
FI965203A7 (fi) Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
EA199900373A2 (ru) Фармацевтические композиции
ATE404211T1 (de) Xenon als nmda-antogonist zur neuroprotektion
DE60019334D1 (de) Antivirale arznei
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
DK1374952T3 (da) Anvendelse af flumazenil ved udvikling af et lægemiddel til behandling af alkoholafhængighed
DK0810883T3 (da) Konjugat indeholdende DTPA og albumin til individuel dosering af lægemidler
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
BR0104345A (pt) Tratamento combinado para a depressão e ansiedade
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
NO982562L (no) Sammensetning for behandling av smerte
SE0004827D0 (sv) Therapeutic compounds
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente